LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Clinical safety rating: safe
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin levels (GLP-1 and GIP), enhancing glucose-dependent insulin secretion and decreasing glucagon secretion. Metformin hydrochloride is a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
| Metabolism | Linagliptin is minimally metabolized (approximately 10%) primarily via CYP3A4; the parent drug is the predominant circulating moiety. Metformin is not metabolized and is excreted unchanged in urine via tubular secretion. |
| Excretion | Linagliptin: ~90% excreted unchanged in feces via biliary excretion (~80%) and ~10% in urine. Metformin: 90-100% excreted unchanged in urine via glomerular filtration and tubular secretion; renal clearance ~510 mL/min. |
| Half-life | Linagliptin: terminal half-life ~120-200 hours, but accumulates with once-daily dosing; effective half-life for MPA inhibition ~12-24 hours. Metformin: terminal half-life ~6.2 hours in good renal function; prolonged in renal impairment. |
| Protein binding | Linagliptin: ~70-80% bound, primarily to albumin and to a lesser extent alpha-1-acid glycoprotein; concentration-dependent. Metformin: negligible (<5%) protein binding. |
| Volume of Distribution | Linagliptin: ~11,000-17,000 L (approx. 150 L/kg for 70 kg); extensive tissue distribution. Metformin: ~1-2 L/kg; distributes into erythrocytes, gastrointestinal wall, and renal tissue. |
| Bioavailability | Linagliptin: oral bioavailability ~30-40%; significantly reduced by high-fat meal (~20%). Metformin: oral bioavailability ~50-60%; decreases at higher doses due to saturation of active absorption; food reduces Cmax by 40%. |
| Onset of Action | Linagliptin: onset of DPP-4 inhibition within 30 minutes; peak inhibition by 1-2 hours. Metformin: onset of glucose-lowering effect within 2-3 days; maximal effect in 1-2 weeks. |
| Duration of Action | Linagliptin: DPP-4 inhibition persists beyond 24 hours due to long half-life; dosing once daily. Metformin: glucose-lowering effect persists 8-12 hours after a dose; sustained with regular dosing. |
Initial: 2.5 mg linagliptin/500 mg metformin hydrochloride orally twice daily; maintenance: up to 2.5 mg linagliptin/1000 mg metformin hydrochloride twice daily with meals.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR < 30 mL/min/1.73 m². If eGFR 30-45 mL/min/1.73 m², reduce metformin dose to 500 mg/day maximum and reassess renal function; linagliptin no dose adjustment. |
| Liver impairment | Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh Class A and B; no specific dose adjustment established. |
| Pediatric use | Not recommended for pediatric patients under 18 years of age due to lack of safety and efficacy data. |
| Geriatric use | Initiate at lowest dose (2.5 mg/500 mg twice daily) and titrate gradually. Monitor renal function closely; avoid use if eGFR < 30 mL/min/1.73 m². |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
| FDA category | Human |
| Breastfeeding | Linagliptin: No human data; excreted in rat milk at concentration 2-10 times maternal plasma. Metformin: Excreted into human milk; relative infant dose approximately 0.5-1% of maternal weight-adjusted dose; M/P ratio unknown. Consider benefits of breastfeeding versus potential risk; limited data suggest compatibility for metformin; linagliptin not recommended due to unknown infant exposure. |
| Teratogenic Risk |
■ FDA Black Box Warning
Lactic acidosis: Metformin-associated lactic acidosis (MALA) is a rare but serious complication; risk factors include renal impairment, hypoxia, sepsis, acute heart failure, hepatic impairment, alcohol abuse, and use of iodinated contrast agents.
| Common Effects | Diarrhea |
| Serious Effects |
["Renal disease or dysfunction (e.g., eGFR <30 mL/min/1.73 m²)","Acute or chronic metabolic acidosis, including diabetic ketoacidosis","Hypersensitivity to linagliptin, metformin, or any component of the product","History of hypersensitivity reactions (e.g., anaphylaxis, angioedema) to DPP-4 inhibitors"]
| Precautions | ["Lactic acidosis","Renal impairment: Assess renal function before initiation and periodically thereafter; contraindicated in eGFR <30 mL/min/1.73 m²","Hypoglycemia: Risk increased when combined with insulin or sulfonylureas","Pancreatitis: Discontinue if pancreatitis is suspected","Heart failure: DPP-4 inhibitors may increase risk of heart failure","Vitamin B12 deficiency: Monitor annually during long-term metformin use","Acute kidney injury: Avoid in severe infections, dehydration, or contrast procedures","Macrovascular outcomes: No conclusive evidence of benefit"] |
Loading safety data…
| Linagliptin: Limited human data; animal studies show no teratogenicity at exposures up to 30 times human exposure. Metformin: First trimester exposure not associated with major malformations; second and third trimester use associated with reduced risk of macrosomia but potential risk of neonatal hypoglycemia and respiratory distress. Combined: Adequate human studies lacking; avoid in first trimester unless benefit outweighs risk. Use during organogenesis (weeks 5-10) warrants careful risk-benefit assessment. |
| Fetal Monitoring | Maternal: Monitor renal function (serum creatinine), hepatic function, blood glucose, HbA1c, and lactic acidosis signs (especially if renal impairment). Fetal/neonatal: Ultrasound for growth assessment; monitor for macrosomia, polyhydramnios; neonatal hypoglycemia and respiratory distress if metformin used in third trimester. |
| Fertility Effects | Metformin may improve fertility in women with PCOS by restoring ovulation; no adverse effects on male fertility. Linagliptin: Animal studies no effect on fertility; human data lacking. Combined: Potential positive effect on female fertility if PCOS is present; no known negative impact. |